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Background: The use of targeted LC-MS/MS methods for protein quantitation in clinical laboratories implies a
careful evaluation of potential sources of analytical interference. In this study, we investigated whether
inflammation, which is associated with both the release of proteolytic enzymes and increased expression of acute
phase protease inhibitors, is affecting the accuracy of a haptoglobin selected reaction monitoring (SRM) assay.
Results: A SRM assay was developed and used to quantify haptoglobin in 57 human serum samples. The SRM
assay had CVs (n = 6) of 12.9% at 698 mg/L and 11.8% at 1690 mg/L. Results of the SRM assay were compared
to those of a commercial immunonephelometric test. Passing-Bablok regression gave a proportional bias of 0.92
(95% CI: 0.82 to 1.04) and a constant bias of 75.40 (95% CI: −71.09 to 251.04), indicating that SRM and
immunonephelometric assays provided comparable results. We then investigated whether the accuracy of the SRM
assay was influenced by the patient’s inflammatory state by assessing the relationship between the serum CRP
concentration and the bias between the two methods. No correlation was found between the SRM/immunoassay
bias and the CRP concentration (Pearson correlation coefficient r = 0.0898).
Conclusions: These data indicate that neither the release of proteolytic enzymes nor the increased level of
protease inhibitors occurring during inflammation processes have a significant impact on the haptoglobin SRM
assay accuracy. Such studies provide important information about potential sources of analytical interferences in
protein SRM assays.
Keywords: Inflammation, Haptoglobin, Protease inhibitor, Quantitative proteomics, Selected reaction monitoring,
Trypsin digestionBackground
Thanks to the development of instruments and proto-
cols, the use in clinical laboratories of liquid chromatog-
raphy coupled to tandem mass spectrometry (LC-MS/
MS) is expanding. A combination of factors explains this
trend. First, very high analytical performances (sensitiv-
ity, scan speed) can be achieved with relatively simple
and entry-level instruments, such as ion trap or triple-
quadrupole mass spectrometers. Second, improvement
of the robustness of LC-MS/MS systems and the develop-
ment of user-friendly software interfaces make the use of* Correspondence: pierre.lescuyer@unige.ch
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unless otherwise stated.LC-MS/MS for routine applications by a non-specialized
team easier. Third, the availability of commercial reagents,
including HPLC columns, mobile phases, calibrators, and
internal standards, together with dedicated support from
vendors for clinical applications greatly simplifies the im-
plementation of a new MS assay. All these factors have
contributed to the democratization of the use of LC-MS/
MS methods in clinical laboratories. Reports from external
quality schemes shows that LC-MS/MS is becoming a
major player in some important clinical areas, such as
therapeutic drug monitoring of immunosuppressants or
measurement of 25-OH-vitamin D and steroid hormones.
It is noteworthy that MS protein assays do not yet fol-
low this trend despite an indubitable and sustained
interest from the clinical chemistry community [1,2].
MS assays may indeed provide a number of advantagesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tein quantification in clinical laboratories, particularly in
terms of multiplexing capabilities and analytical specifi-
city. Hoofnagle and Werner have thus described differ-
ent situations where immunoassay limitations could be
overcame by the use of MS. This includes the lack of
inter-assays standardization due to the use of different
antibodies recognizing different epitopes and the analyt-
ical interferences related to the presence of autoanti-
bodies or anti-reagent antibodies in patients’ serum [3].
Moreover, numerous selected reaction monitoring
(SRM) protein assays have been developed for the quan-
tification of proteins of clinical interest in serum or
urine. Some of these studies included a complete ana-
lytical validation and a comparison with a reference
method to fulfill criteria used in laboratory medicine for
method qualification. The list includes albumin [4,5],
alpha-1-antitrypsin [6], apolipoproteins A1 and B [7],
parathyroid hormone [8,9], thyroglobulin [10,11], and
troponin I [12]. However, at the present time, the appli-
cation of these methods in a clinical setting, if any, is re-
stricted to one or a few laboratories. One reason is
probably the complexity of the workflow used for sample
preparation, involving trypsin digestion and, often, an
immunoaffinity step for target peptide enrichment
[8-12]. The ability to run such assays on a routine basis
remains then restricted to a few specialized laboratories
with dedicated instruments and team. In addition, these
SRM protein assays have their own specific problems in
term of analytical interferences. Trypsin digestion, in
particular, was shown to be a major factor of analytical
imprecision [13]. Peptidase activities present in bio-
logical samples may also be a source of analytical errors
by degrading peptides generated from the target protein
or heavy isotope-labeled peptides used as internal refer-
ence standards [14,15]. Therefore, the biological and
technical factors that can impact the performances of
SRM protein assays must be carefully assessed before
considering applying such methods in routine clinical
practice.
According to what has been shown regarding the crit-
ical influence of trypsin digestion and peptide stability
on SRM protein assay performances, inflammation,
which is present in a wide range of disease states, repre-
sent a particular concern in terms of analytical interfer-
ences. Inflammation is indeed associated first with the
release of various proteolytic enzymes [16] that may
affect protein and peptide stability in serum samples.
Second, inflammation is associated with an increased ex-
pression of acute phase proteins with antitrypsin activities,
such as alpha-1-antitrypsin or alpha-2-macroglobulin
[17,18]. These protease inhibitors may interfere with the
protein digestion step of the assay. In order to evaluate
the impact of the patient’s inflammatory state on theaccuracy of SRM-based protein quantification, we devel-
oped a SRM assay for the quantification of serum hapto-
globin. Haptoglobin is a protein routinely measured in
laboratory medicine, in particular for the detection of
hemolytic anemia [19]. This SRM assay was then com-
pared to a commercial immunonephelometric test used
as reference quantification method. Finally, we determined
whether the serum C reactive protein (CRP) concentra-
tion, a marker of the inflammatory state [20], had an im-
pact on the haptoglobin SRM assay inaccuracy, which was
defined as the bias between the LC-MS/MS and the
immunonephelometric methods.
Results and discussion
Calibration of the haptoglobin SRM assay
Calibration of the SRM assay was performed using the
commercial haptoglobin standard solution provided for
the nephelometric immunoassay. A four points calibra-
tion was built ranging from 115 mg/L to 1150 mg/L.
Precision of the calibration process was evaluated by
comparing data from three independent calibrations
(different trypsin digestion) performed on the same day.
Calibration curves are presented in Figure 1A. CVs of
peak area ratios obtained for the different calibration
points ranged from 6.5 to 7.8%. Two additional calibra-
tions were performed on two different days (Figure 1B).
When including intra-day and inter-days five calibration
data, the overall CVs of peak area ratios obtained for the
different calibration points ranged from 6.4 to 17%. The
highest CV was obtained for the lowest concentration of
the calibration curve. These data demonstrated the re-
producibility of the calibration process both intra- and
inter-days.
Haptoglobin quantification with the SRM assay
Haptoglobin concentration was measured by SRM in
serum samples from 57 patients in two independent
series. Two control sera were analyzed in triplicate in
each series. CVs obtained (n = 6) were 12.9% at 698 mg/
L for the N Protein Control SL Low (target value:
650 mg/L) and 11.8% at 1690 mg/L for the N Protein
Control SL high (target value: 1740 mg/L). All results
from patient samples were within the measuring range,
except two sera with a haptoglobin concentration above
4600 mg/L and five samples with a concentration below
115 mg/L. Results are listed in Additional file 1.
Comparison with the immunonephelometric assay
Results from the SRM assay were compared with data of
the commercial nephelometric immunoassay obtained
on the same samples (Additional file 1). Passing-Bablok
regression was performed using results within the
measuring range of the two assays. A total of 50 values
were included over a concentration range from 206 to
Figure 1 Calibration of the haptoglobin SRM assay. External calibration of the SRM assay was performed with the N Protein Standard SL
(Siemens) used for the nephelometric assay calibration. Calibration solution was prepared according to the manufacturer’s instructions to a final
concentration of 1150 mg/L. Dilutions were made in water at 575, 230, and 115 mg/L. A four points calibration was built ranging from 115 mg/l
to 1150 mg/L. Each calibration point was injected in triplicate. A) Calibration curves obtained from three independent calibrations (different
trypsin digestion) performed on the same day. B) Calibration curves obtained from two independent calibrations (different trypsin digestion)
performed on different days.
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the two methods provided overall similar results. The
proportional bias was 0.92 (95% CI: 0.82 to 1.04) and the
constant bias was 75.40 (95% CI: −71.09 to 251.04).
Nevertheless, as shown on the Bland-Altman plot,
important differences were observed for some samples
between the two methods (Figure 2B).
Regarding samples not included in the Passing-Bablok
analysis, discordant results between the SRM assay and
the nephelometric immunoassay were obtained for only
one serum. In this case, a haptoglobin concentration of
560 mg/L was found by immunonephelometry while it
was below the limit of quantification (<115 mg/L) of the
SRM assay. Otherwise, two samples measured above the
measuring range of the nephelometric immunoassay(>4400 mg/L) were also found above the measuring
range of the SRM assay (>4600 mg/L) and four samples
measured below the measuring range of the nephelomet-
ric immunoassay (<75 mg/L) were also found below the
measuring range of the SRM assay (<115 mg/L).
Influence of inflammatory state of the patient on the SRM
assay accuracy
Inflammation is associated with the release of various
proteolytic enzymes, including elastin, cathepsins and
matrix metalloproteinases, which act as important medi-
ators of the inflammatory response [16]. In parallel to
that, inflammation induces a strong increase of the
serum level of various acute phase protease inhibitors,
such as alpha-1-antitrypsin, alpha-1-antichimotrypsin or
Figure 2 Comparison of the haptoglobin SRM assay and the nephelometric immunoassay. A) Passing-Bablok regression. B) Bland-Altman
plot. Statistical analysis and graphics were made using Analyze-it V2.26.
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these two events have an impact on the accuracy of
SRM based protein assays. First, proteolytic enzymes
may alter the in vitro stability of both endogenous pro-
tein/peptides and isotope-labeled internal standard pep-
tides. Second, the serum concentration of acute phase
protease inhibitors reaches the g/L range during inflam-
matory states and this may inhibit the trypsin digestion
step of the SRM assay. We therefore investigated
whether the extent of the bias observed between the
haptoglobin immunonephelometric assay used as refer-
ence method and the LC-MS/MS assay was correlated
to the inflammatory state of the patient. The bias was
calculated using the following formula: [haptoglobin
SRM (mg/L) - haptoglobin nephelometry (mg/L)]/[mean
(mg/L) of haptoglobin SRM and haptoglobin nephelom-
etry] × 100. Inflammatory state of the patient was deter-
mined by measuring the serum CRP concentration,
which is the gold standard marker of inflammation in la-
boratory medicine [20]. Results of the linear regression
analysis are presented in Figure 3. Samples yieldingresults out of the measuring range of one of the two as-
says were excluded from the analysis. The following lin-
ear regression equation was obtained: y (bias) = 0.0536 ×
(CRP) – 0.1607. Pearson correlation coefficient was
0.0898. As shown in Figure 3, some samples with CRP
values within the normal range (<10 mg/L) were associ-
ated with a strong bias (>20%), either positive or nega-
tive, whereas the three samples with CRP values above
100 mg/L only presented minor bias (<10%). These data
indicate that differences observed between results of the
SRM and the immunonephelometric assays for some
samples cannot be explained by analytical interferences
related to the patient’s inflammatory state.
Conclusions
A LC-MS/MS assay was developed for SRM quantifica-
tion of haptoglobin in human serum samples. This assay
yielded results comparable to those of a commercial
immunonephelometric assay routinely used in clinical
laboratories. We then demonstrated that the bias ob-
served for some samples between the two analytical
Figure 3 Influence of inflammation on the haptoglobin SRM assay accuracy. The bias between the SRM assay and the nephelometric
immunoassay was calculated as follows: [haptoglobin SRM (mg/L) - haptoglobin nephelometry (mg/L)]/[mean (mg/L) of haptoglobin SRM and
haptoglobin nephelometry] × 100. The serum CRP concentration was measured using a commercial turbidimetric immunoassay on an automated
clinical chemistry analyzer. Graphic and linear regression analyses were made with Excel 2008.
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marker of inflammation. These data suggest that neither
the release of proteolytic enzymes nor the increase in
protease inhibitors level occurring during inflammation
processes have a significant impact on the SRM assay ac-
curacy. The differences observed between the two hapto-
globin assays could thus be related to a combination of
other factors, such as SRM assay imprecision and poten-
tial influence of other preanalytical variables [21]. In-
terferences affecting the nephelometric immunoassay
accuracy may also be a possible explanation [3]. Regard-
ing the possibility of generalizing the conclusion that in-
flammation does not significantly impact MS protein
assay accuracy, two aspects must be distinguished. First,
the stability of endogenous protein/peptides and heavy
labeled internal standards in serum samples was shown
to be species-dependent [15,21]. Therefore, the sensitiv-
ity of this parameter to inflammation-associated peptid-
ase/proteolytic activities must probably be evaluated for
each SRM assay. In contrast, trypsin is the proteolytic
enzyme used in the vast majority of bottom-up prote-
omic studies, including targeted protein quantitative as-
says. Our data suggest that this step of the sample
processing is not sensitive to acute phase protease inhibi-
tors present in serum samples. However, it is important
to consider that this effect could vary depending on the
trypsin digestion protocol used.
Methods
Chemicals
All chemicals were obtained from Sigma-Aldrich (Saint-
Louis, MO), except water and acetonitrile from Romil
(Cambridge, UK).Serum samples
Serum samples used in this study were collected at the
University Hospitals of Geneva by experienced nurses in
the context of standard patient care. The use of these
human specimens was approved by the Ethical Commit-
tee for Research on Human Being of the Geneva state.
Blood samples were collected on BD Vacutainer™ SST II
Advance tubes and were centrifuged at 3’000 g for 5 -
minutes at room temperature upon reception at the
laboratory. Measurement of the serum haptoglobin con-
centration was performed in the Division of Laboratory
Medicine by immunonephelometry assay within 3 hours
after centrifugation. The serum left over was stored
at −80°C for MS analysis within two hours. Frozen sera
were thawed and centrifuged at 3’000 g for 5 minutes at
room temperature before MS analysis. Serum samples
were submitted to a maximum of two freeze/thaw cycles.
Analysis of haptoglobin by immunonephelometric assay
Haptoglobin was measured on a BN ProSpec nephelom-
eter (Siemens, Marburg, Germany) using the N Anti-
serum Anti-Human Haptoglobin (Siemens) according to
the manufacturer’s instructions. The assay had inter-
assay CVs (n = 45) of 1.57% at 675 mg/L and 1.70% at
1394 mg/L. The limit of quantification was 75 mg/L.
The reference range used at the Geneva University Hos-
pitals for this assay is 412 to 1693 mg/L.
Analysis of CRP by turbidimetric assay
CRP was measured on a UniCel DxC 880i clinical chem-
istry analyzer (Beckman Coulter, Brea, CA) using the
Synchron CRP reagents (Beckman Coulter) according to
the manufacturer’s instructions. The assay had inter-
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37.2 mg/L. The limit of quantification was 1 mg/L. The
reference range used at the Geneva University Hospitals
for this assay is <10 mg/L.
LC-MS/MS assay
External calibration and quality controls
External calibration of the SRM assay was performed
with the N Protein Standard SL (Siemens) used for the
nephelometric immunoassay calibration. Calibration so-
lution was prepared according to the manufacturer’s
instructions to a final concentration of 1150 mg/L. Dilu-
tions were made in 25 mM aqueous ammonium bicar-
bonate (BA) at 575, 230, and 115 mg/L, divided into
aliquots and frozen at −80°C until used. Each standard
was injected in triplicate. In a few cases, one of the three
replicates was removed from the calculation (relative
error > 35% compared to the 2 other points).
Assessment of the SRM assay precision was performed
using the High and Low N Protein Controls SL (Siemens)
that were used for the nephelometric immunoassay.
Peptides selection
Two peptides from the haptoglobin beta chain were used
in the SRM assay: VGYVSGWGR and VTSIQDWVQK
(Additional file 2). These peptides were selected using
the following process. Three aliquots of serum from a
patient sample with a haptoglobin concentration mea-
sured at 2.66 g/L by immunonephelometry were digested
as described in the Sample Preparation section. Digested
samples were analyzed by RP-LC-MS/MS on a LTQ
Orbitrap velos Pro (Thermo Electron, San Jose, CA,
USA) equipped with a NanoAcquity system (Waters,
Milford, MA, USA). Of the 13 peptides identified in
common from the three samples, 7 were found to be
proteotypic using SRMAtlas (www.srmatlas.org/), Pep-
tideAtlas (www.peptideatlas.org/), and BLAST (http://
blast.ncbi.nlm.nih.gov/Blast.cgi). The two peptides used
in the SRM assay were selected from this list of proteo-
typic peptides based on the following criteria: reproduci-
bility of the retention time, peak shape, absence of
matrix interferences, limit of detection, calibration curve
linearity, and the consistency of the collision energy for
peptide fragmentation. Isotope-labeled peptides used as
internal standards were obtained from JPT Peptide
Technologies (Berlin, Germany) (Additional file 2). Ly-
ophilized heavy peptides (26 nmol) were dissolved in
100 μl of 5% acetonitrile (ACN), 0.1% formic acid (FA).
A volume of 5 μL of this stock solution was diluted then
in 200 μL 5% ACN, 0.1% FA.
Sample preparation
A volume of 5 μl of calibrator, control or serum sample
was mixed with 45 μl of 25 mM BA. Reduction,alkylation of cysteines, and trypsin digestion were per-
formed using a protocol adapted from Proc et al. [22],
as described below. The mixture was further diluted
with 238.6 μl of 25 mM BA. A volume of 32.1 μl of
50 mM tris (2-carboxyethyl)phosphine (TCEP) was
added and the mixture was incubated 30 min at 60°C.
Then, 35.6 μl of 100 mM iodoacetamide was added and
the mixture was incubated 30 min in the dark at 37°C.
At the end of the incubation, 100 μl of methanol were
added followed by 43.8 μl of a trypsin solution at
0.4 mg/ml. Digestion was performed at 37°C for 4 h and
stopped with 80 μl of 0.1% FA. After evaporation, sam-
ples were desalted using a C18 Macro SpinColumn
(Harvard apparatus, Holliston, MA). After sample load-
ing, the column was washed twice with 5% ACN, 0.1%
FA and elution was performed twice with 150 μL of 50%
ACN, 0.1% FA. The flow-through was dried under vac-
uum, dissolved in a volume of 200 μL 5% ACN, 0.1% FA
and 5 μL of diluted heavy peptides was added.
LC-MS/MS analysis
HPLC separation was performed on an Accela system
(Thermo-Scientific, Waltham, MA) using a Hypersil
GOLD Guard 10 × 1 mm 3 μm particle precolumn
(Thermo-Scientific) and a Hypersil GOLD C18 100 ×
1 mm 1.9 μm particle column (Thermo-Scientific). Mo-
bile phases used for the analysis were: A) 0.2% FA in
water (v/v) and B) 0.2% FA in ACN (v/v). Sample (10 μL)
was injected into the HPLC system at an initial condition
of 5% B during 1 min and rising to 30% after 14 min. The
column was then washed at 100% B for 1 min before
returning to starting conditions in 7 min. A constant flow
rate was set at 80 μL/min and the column compartment
was set at a constant temperature of 50°C. The HPLC
system was hyphenated to TSQ Quantum Access triple
stage quadrupole equipped with a heated electrospray
ionization probe (Thermo-Scientific). Peptides were
quantified using SRM in positive ion mode under the fol-
lowing conditions: ionization voltage, 3500 V; sheath gas
pressure, 10 arbitrary units; auxiliary gas pressure, 1 arbi-
trary units; capillary temperature, 270°C; Tube lens offset,
92; Collision pressure, 1.5. Two proteotypic peptides
were analyzed in the assay: VGYVSGWGR was used for
the quantification of haptoglobin and VTSIQDWVQK
was used as verifier. Examples of extracted ion chromato-
grams for these two peptides are presented in Additional
file 3. We determined peak areas for the endogenous and
internal standard heavy peptides in Xcalibur 2.1.0.1139
(Thermo-Scientific). Three transitions were used per
peptide (Additional file 2). The transitions per peptide or
internal standard were summed. The response of each
peptide was calculated as the ratio of the peak area of the
endogenous peptide to the peak area of the corresponding
heavy peptide used as internal standard. Patient samples
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standard (1150 mg/L) were reanalyzed after dilution in
25 mM BA. A maximum dilution of ¼ was used so that
the maximum concentration measured with the hapto-
globin SRM assay was 4600 mg/L.
Statistics
All graphics and statistics were made with Excel 2008,
except Passing-Bablok regression [23] and Bland-Altman
plot [24], which were made using Analyze-it V2.26.
Additional files
Additional file 1: Haptoglobin concentrations, CRP concentration,
and bias values obtained for individual serum samples.
Additional file 2: Table S1. Transitions used in the haptoglobin SRM assay.
Additional file 3: Supplementary Figure 1. Extracted ion chromatograms
of the VGYVSGWGR peptide (quantifier) and the VTSIQDWVQK peptide
(verifier).
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